iOmx Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class cancer immunotherapies addressing novel immune-checkpoints hijacked by cancer cells. Using the foundational iOTarg discovery platform, iOmx has identified several new tumor-associated immune-checkpoints and is advancing a pipeline of promising drug candidates that have the potential to address cancers that are resistant to current immunotherapies. For more details, please visit iomx.com.